查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1993611

全球抗生物膜劑市場：按產品、分子、傷口類型、最終用戶和地區分類－市場規模、產業趨勢、機會分析和未來預測（2026-2035年）

Global Anti-Biofilm Agents Market: By Product, Molecule, Wound Type, End User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 290 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球抗生物膜藥物市場正快速擴張，反映出先進感染控制策略在醫療機構中日益成長的重要性。該市場在2025年的價值為18.4億美元，預計未來十年將成長一倍以上，到2035年達到43.2億美元。該成長意味著2026年至2035年預測期間的年複合成長率（CAGR）為8.9%，顯示市場對有效控制生物膜相關感染疾病的產品有著穩定且持續的需求。

抗菌素抗藥性（AMR）日益嚴峻的挑戰是推動市場強勁擴張的主要因素，而抗菌素抗藥性已成為全球重大的健康問題。隨著細菌對傳統抗生素的抗藥性不斷增強，治療和控制生物膜相關感染疾病的難度也隨之增加。生物膜如同微生物群落的保護屏障，使其免受抗菌藥物和宿主免疫反應的攻擊，延長感染疾病，並增加根除難度。這種情況使得人們迫切需要能夠破壞生物膜結構、增強抗菌藥物療效並最終改善患者預後的專用抗生物膜藥物。

顯著的市場趨勢

現今的抗生物膜劑市場呈現出動態的格局，既有老牌化工企業和醫療集團，也有眾多創新的中小型生技公司。這種格局造就了競爭激烈的市場環境，市場整合與分散並存，既促進了該領域的穩定發展，也推動了快速創新。大型跨國公司憑藉著雄厚的資源、成熟的生產能力和廣泛的分銷網路，保持著強大的市場地位。

主要企業包括3M、Smith & Nephew、Molnlycke Health Care、Coloplast A/S、ConvaTec Inc.、Hartmann Group、Medtronic等全球知名公司。這些行業領導者憑藉數十年來提供的各種先進創傷護理和感染控制產品，建立了良好的聲譽。他們豐富的產品系列涵蓋敷料、凝膠、外用抗菌劑和具有抗生物膜特性的醫療設備，可滿足醫院和門診環境中各種不同的臨床需求。

同時，許多小規模生物技術公司的湧現也帶來了新的創新和專業知識。這些公司通常專注於開發特異性生物膜相關感染疾病的新型分子、遞送系統或診斷工具。他們的創新解決方案能夠滿足尚未滿足的臨床需求，並提供挑戰傳統方法的差異化產品。

主要成長要素

抗生物膜藥物市場成長和創新的主要驅動力是日益嚴重的抗菌素抗藥性（AMR）危機。到2025年，AMR已成為一項重大的全球健康威脅，與世界各地許多死亡病例直接相關。這一令人擔憂的趨勢凸顯了開發有效策略和產品以對抗抗藥性感染疾病（尤其是生物膜形成細菌引起的感染疾病）的緊迫性。生物膜是由微生物組成的複雜聚集體，包裹在保護性基質中，使細菌能夠逃避傳統的抗生素治療，使感染疾病更持久且難以根除。

新機會的趨勢

奈米技術在創傷護理的應用代表著一個充滿前景且快速發展的新興機會，預計將顯著推動市場成長。奈米技術是指在分子或原子層面操控材料，進而開發出性能和功能更強大的創傷護理產品。這種尖端技術能夠更精準地標靶化和控制治療藥物的釋放，以傳統創傷護理產品無法企及的方式提高治療效果並加速癒合過程。

最佳化障礙

截至2025年，美國食品藥物管理局（FDA）和環境保護署（EPA）等監管機構對產品必須正式標註為「抗生物膜」產品仍維持嚴格的要求。這些嚴格的標準目的是確保任何關於破壞或預防生物膜的說法都以可靠的科學證據為支撐，並透過標準化的測試通訊協定檢驗。由於生物膜是由微生物組成的複雜結構，其行為與空氣傳播的細菌不同，因此，證明其對生物膜的有效性需要比傳統抗菌產品更專業、更具挑戰性的測試方法。

目錄

第1章 執行摘要：全球抗生物膜劑市場

第2章 分析方法與框架

  • 分析目的
  • 產品概述
  • 市場區隔
  • 定性研究
    • 一手和二手資訊
  • 量化研究
    • 一手和二手資訊
  • 主要調查受訪者組成：依地區分類
  • 本報告的前提條件
  • 市場規模估算
  • 資料檢驗

第3章 全球抗生物膜劑市場概覽

  • 產業價值鏈分析
    • 原物料供應商
    • 製造商和製藥公司
    • 銷售代理商和服務供應商
    • 最終用戶
  • 產業展望
    • 抗菌敷料的交易趨勢
    • 主要買家和供應商
    • 抗生物膜技術的最新進展
    • 抗生物膜產品：研發管線概覽
  • PESTLE分析
  • 波特五力分析
    • 供應商議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場成長及前景
    • 市場獲利估算與預測（2020-2035）
    • 價格趨勢分析

第4章 全球抗生物膜劑市場分析

  • 競爭格局概述
    • 市場集中度
    • 企業市場占有率分析（以金額為準，%）（2025年）
    • 競爭對手分析與基準測試

第5章 全球抗生物膜劑市場分析

  • 市場動態和趨勢
    • 成長要素
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場規模及預測（2020-2035）
    • 依產品
    • 依分子
    • 依傷口類型
    • 依最終用戶
    • 依地區

第6章 北美市場分析

第7章 歐洲市場分析

第8章 亞太市場分析

第9章 中東和非洲市場分析

第10章 南美市場分析

第11章 公司簡介

  • Coloplast A/S
  • Convatec Inc.
  • Imbed Biosciences
  • Molnlycke AB
  • Smith+Nephew
  • Solventum
  • URGO MEDICAL
  • Other Prominent Players

第12章 附錄

簡介目錄
Product Code: AA02261702

The global anti-biofilm agents market is experiencing rapid expansion, reflecting the growing importance of advanced infection control strategies in healthcare. Valued at USD 1.84 billion in 2025, the market is projected to more than double over the next decade, reaching an estimated valuation of USD 4.32 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 8.9% during the forecast period from 2026 to 2035, indicating steady and sustained demand for products that effectively combat biofilm-associated infections.

The driving force behind this robust market expansion is the escalating challenge posed by antimicrobial resistance (AMR), which has become a critical global health concern. As bacteria increasingly develop resistance to conventional antibiotics, infections associated with biofilms become harder to treat and control. Biofilms act as protective barriers that shield microbial communities from antimicrobial agents and the host immune response, making infections persistent and difficult to eradicate. This situation has created an urgent need for specialized anti-biofilm agents that can disrupt these structures, enhance antimicrobial efficacy, and ultimately improve patient outcomes.

Noteworthy Market Developments

The anti-biofilm agents market today is characterized by a dynamic mix of well-established chemical and healthcare conglomerates alongside a diverse array of smaller, innovative biotech companies. This blend creates a competitive landscape where market consolidation coexists with fragmentation, driving both stability and rapid innovation within the sector. Large multinational corporations bring extensive resources, established manufacturing capabilities, and broad distribution networks that enable them to maintain a strong foothold in the market.

Among the major players dominating the market are globally recognized companies such as 3M, Smith & Nephew, Molnlycke Health Care, Coloplast A/S, ConvaTec Inc., Hartmann Group, and Medtronic. These industry leaders have built their reputations over decades by supplying a wide range of advanced wound care and infection control products. Their extensive product portfolios often include dressings, gels, topical antimicrobials, and medical devices that incorporate anti-biofilm properties, catering to various clinical needs across hospital and outpatient settings.

At the same time, the presence of numerous smaller biotech firms introduces a layer of innovation and specialization. These companies often focus on developing novel molecules, delivery systems, or diagnostic tools specifically targeting biofilm-related infections. Their innovative solutions can address unmet clinical needs and offer differentiated products that challenge traditional approaches.

Core Growth Drivers

The primary catalyst driving growth and innovation in the anti-biofilm agents market continues to be the escalating Antimicrobial Resistance (AMR) crisis. As of 2025, AMR has emerged as a major global health threat, directly contributing to a significant number of deaths worldwide. This alarming trend has heightened the urgency to develop effective strategies and products that can combat resistant infections, particularly those involving biofilm-forming bacteria. Biofilms, which are complex communities of microorganisms encased in a protective matrix, enable bacteria to evade conventional antimicrobial treatments, making infections more persistent and difficult to eradicate.

Emerging Opportunity Trends

The adoption of nanotechnology in wound care represents a promising and rapidly emerging opportunity that could significantly drive growth within the market. Nanotechnology involves the manipulation of materials at the molecular or atomic level, enabling the development of wound care products with enhanced properties and functionalities. This cutting-edge approach allows for more precise targeting and controlled delivery of therapeutic agents, which can improve the effectiveness of treatments and accelerate the healing process in a way that traditional wound care products cannot match.

Barriers to Optimization

As of 2025, regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA) maintain stringent requirements for a product to be officially labeled as "Anti-Biofilm." These rigorous standards are designed to ensure that any claims related to biofilm disruption or prevention are supported by robust scientific evidence and validated through standardized testing protocols. Because biofilms are complex, structured communities of microorganisms that behave differently from free-floating bacteria, demonstrating efficacy against them requires specialized and often more challenging testing methods compared to those used for traditional antimicrobial products.

Detailed Market Segmentation

By Molecule, Silver-based solutions have consistently held the largest share in the anti-biofilm agents market due to their broad-spectrum antimicrobial properties and their widespread acceptance among clinicians for managing bioburden in high-risk or infected wounds. Silver's efficacy in targeting a wide range of microorganisms, including bacteria, fungi, and some viruses, makes it a reliable choice when topical antimicrobial action is critical to preventing infection and promoting wound healing. This broad coverage is especially important in clinical settings where wounds are prone to contamination or already infected, necessitating potent and dependable agents that can reduce microbial load and disrupt biofilm formation.

By Wound Type, chronic wounds represent the largest and most significant demand segment within the anti-biofilm agents market due to their high prevalence and the extended duration of treatment they typically require. Unlike acute wounds, which usually heal within a predictable timeframe, chronic wounds persist for weeks or months, creating an environment where biofilms are more likely to develop and complicate healing. The presence of biofilms in these wounds significantly increases the risk of infection and delays recovery, necessitating the use of specialized anti-biofilm agents to disrupt these bacterial communities and support effective treatment.

By End Users, hospitals stood out as the dominant end-users in the anti-biofilm agents market in 2025, reflecting their central role in managing the most critical and complex wound care cases. These facilities handle the highest-acuity wounds, including those that are severe, chronic, or slow to heal, which are particularly susceptible to biofilm-related infections. Additionally, hospitals perform the highest-risk surgeries where infection control is paramount, making the use of effective anti-biofilm agents essential to prevent complications and improve patient outcomes. Their established and standardized purchasing systems further facilitate the widespread adoption of these products on a large scale, enabling hospitals to procure and deploy the necessary wound care supplies.

By Product Type, dressings remain the top-performing product category in the anti-biofilm agents market due to their unique ability to deliver antibiofilm chemistry directly to the wound-exudate interface in a scalable and effective manner. These dressings are designed to maintain continuous contact with the wound environment, ensuring that the active agents consistently inhibit biofilm formation and promote healing. The direct application and sustained presence of these antimicrobial substances at the wound site make dressings particularly effective in managing chronic wounds, where biofilms pose a significant challenge to recovery.

Segment Breakdown

By Product

  • Dressings
  • Ointments / Gels
  • Powders

By Molecule

  • Silver
  • Iodine
  • Honey
  • Others

By Wound Type

  • Chronic Wounds
  • Acute Wounds

By End User

  • Hospitals
  • Wound Clinics
  • Home Care Settings
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Geography Breakdown

  • North America stands as the largest revenue contributor to the global anti-biofilm agents market, a position supported by several key factors that create a favorable environment for market growth. The region benefits from mature hospital systems known for their advanced infrastructure and high standards of patient care, which drive the adoption of innovative medical technologies. Additionally, the high per-patient healthcare spending in North America enables widespread access to premium treatments, including advanced wound-care products that incorporate anti-biofilm properties.
  • Recent market assessments estimate North America's share of the anti-biofilm agents market at approximately 36.95% in 2024, often rounded to about 37-38% in industry discussions. This substantial slice of the global market underscores North America's status as the focal point of current demand concentration. The region's dominance is not merely a result of economic factors but is also structurally linked to its clinical burden, particularly the high prevalence of chronic wounds.

Leading Market Participants

  • Coloplast A/S
  • Convatec Inc.
  • Imbed Biosciences
  • Molnlycke AB
  • Smith+Nephew
  • Solventum
  • URGO MEDICAL
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Anti-Biofilm Agents Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Anti-Biofilm Agents Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material Suppliers
    • 3.1.2. Manufacturers and Formulators
    • 3.1.3. Distributors and Service Providers
    • 3.1.4. End Users
  • 3.2. Industry Outlook
    • 3.2.1. Trade Performance of Antimicrobial Dressings
    • 3.2.2. Major Buyers & Suppliers
    • 3.2.3. Recent Innovations in Anti-Biofilm Technology
    • 3.2.4. Pipeline Overview of Anti-Biofilm Products
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis

Chapter 4. Global Anti-Biofilm Agents Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Anti-Biofilm Agents Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Product Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Dressings
        • 5.2.1.1.2. Ointments / Gels
        • 5.2.1.1.3. Powders
    • 5.2.2. By Molecule
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Silver
        • 5.2.2.1.2. Iodine
        • 5.2.2.1.3. Honey
        • 5.2.2.1.4. Others
    • 5.2.3. By Wound Type
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Chronic Wounds
        • 5.2.3.1.2. Acute Wounds
    • 5.2.4. By End User
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Hospitals
        • 5.2.4.1.2. Wound Clinics
        • 5.2.4.1.3. Home Care Settings
        • 5.2.4.1.4. Others
    • 5.2.5. By Region
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. North America
          • 5.2.5.1.1.1. The U.S.
          • 5.2.5.1.1.2. Canada
          • 5.2.5.1.1.3. Mexico
        • 5.2.5.1.2. Europe
          • 5.2.5.1.2.1. Western Europe
            • 5.2.5.1.2.1.1. The UK
            • 5.2.5.1.2.1.2. Germany
            • 5.2.5.1.2.1.3. France
            • 5.2.5.1.2.1.4. Italy
            • 5.2.5.1.2.1.5. Spain
            • 5.2.5.1.2.1.6. Rest of Western Europe
          • 5.2.5.1.2.2. Eastern Europe
            • 5.2.5.1.2.2.1. Poland
            • 5.2.5.1.2.2.2. Russia
            • 5.2.5.1.2.2.3. Rest of Eastern Europe
        • 5.2.5.1.3. Asia Pacific
          • 5.2.5.1.3.1. China
          • 5.2.5.1.3.2. India
          • 5.2.5.1.3.3. Japan
          • 5.2.5.1.3.4. South Korea
          • 5.2.5.1.3.5. Australia & New Zealand
          • 5.2.5.1.3.6. ASEAN
            • 5.2.5.1.3.6.1. Indonesia
            • 5.2.5.1.3.6.2. Malaysia
            • 5.2.5.1.3.6.3. Thailand
            • 5.2.5.1.3.6.4. Singapore
            • 5.2.5.1.3.6.5. Rest of ASEAN
          • 5.2.5.1.3.7. Rest of Asia Pacific
        • 5.2.5.1.4. Middle East & Africa
          • 5.2.5.1.4.1. UAE
          • 5.2.5.1.4.2. Saudi Arabia
          • 5.2.5.1.4.3. South Africa
          • 5.2.5.1.4.4. Rest of MEA
        • 5.2.5.1.5. South America
          • 5.2.5.1.5.1. Argentina
          • 5.2.5.1.5.2. Brazil
          • 5.2.5.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Product Type
      • 6.2.1.2. By Molecule
      • 6.2.1.3. By Wound Type
      • 6.2.1.4. By End User
      • 6.2.1.5. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Product Type
      • 7.2.1.2. By Molecule
      • 7.2.1.3. By Wound Type
      • 7.2.1.4. By End User
      • 7.2.1.5. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Product Type
      • 8.2.1.2. By Molecule
      • 8.2.1.3. By Wound Type
      • 8.2.1.4. By End User
      • 8.2.1.5. By Country

Chapter 9. Middle East & Africa Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Product Type
      • 9.2.1.2. By Molecule
      • 9.2.1.3. By Wound Type
      • 9.2.1.4. By End User
      • 9.2.1.5. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Product Type
      • 10.2.1.2. By Molecule
      • 10.2.1.3. By Wound Type
      • 10.2.1.4. By End User
      • 10.2.1.5. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Coloplast A/S
  • 11.2. Convatec Inc.
  • 11.3. Imbed Biosciences
  • 11.4. Molnlycke AB
  • 11.5. Smith+Nephew
  • 11.6. Solventum
  • 11.7. URGO MEDICAL
  • 11.8. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators